Annovis Bio, Inc. (NYSE: ANVS) shares gained Thursday. The Malvern, Pa.-based company, a late-stage clinical drug platform firm pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects beyond symptomatic relief.
"Alzheimer's disease is multifactorial, and targeting just one of its causes has historically yielded limited therapeutic benefit," commented CEO Maria Maccechini, Ph.D.. "What makes buntanetap truly promising is its ability to target multiple neurotoxic proteins simultaneously and interrupt the toxic cascade—something we have long believed was necessary for meaningful progress. These biomarker results validate our preclinical and earlier clinical findings and reinforce our confidence that we are on the right track."
Buntanetap has previously demonstrated clinical benefits in the Phase 2/3 study, where mild AD patients saw significant cognitive improvement. The convergence of these findings with the novel biomarker data, which indicate reduced inflammation and improved neuronal health, underscore buntanetap’s promise as a potential disease-modifying therapy that may fundamentally alter the course of Alzheimer’s. Buntanetap is currently being evaluated in a pivotal Phase 3 trial in early AD, which is actively enrolling and treating patients across the U.S.
The study is designed to have a six-month readout focused on symptomatic improvement and an 18-month readout aimed at assessing disease modification.
ANVS shares captured 14 cents, or 6.2%, to $2.41.
Related Stories
